Literature DB >> 9066611

p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.

V Esposito1, A Baldi, A De Luca, P P Claudio, G Signoriello, A Bolognese, P Centonze, G G Giordano, M Caputi, F Baldi, A Giordano.   

Abstract

We evaluated tissues for the overexpression of p53 protein in 35 malignant mesotheliomas and 20 reactive pleural hyperplasias, obtained from open biopsies or pleurectomies. Of the 35 neoplasms investigated, 30 (85.7%) displayed positive nuclear staining for p53. No staining was seen in any specimens of hyperplasia. We found no significant statistical difference in p53 expression when we compared p53 overexpression in the different histological subtypes of mesotheliomas. Moreover, p53 overexpression did not correlate in a statistical manner with survival. We conclude that p53 overexpression is a frequent feature of pleural mesothelioma and is useful for routine differentiating between malignant and non-neoplastic mesothelial alterations. The reason for p53 overexpression in mesothelioma, however, remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066611

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.

Authors:  A Baldi; A M Groeger; V Esposito; R Cassandro; G Tonini; T Battista; M P Di Marino; B Vincenzi; M Santini; A Angelini; R Rossiello; F Baldi; M G Paggi
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

2.  Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status.

Authors:  Julia R Naso; Basile Tessier-Cloutier; Janine Senz; David G Huntsman; Andrew Churg
Journal:  Mod Pathol       Date:  2021-09-08       Impact factor: 7.842

3.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

4.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

5.  p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.

Authors:  So-My Koo; Soo-Taek Uh; Dong Won Kim; Ki-Up Kim; Yang-Ki Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.